NEWS STS Data: Mitral Valve Cases Are Fastest-Growing CV Surgical Intervention in North America

Mitral valve repairs and replacements now constitute the most rapidly growing segment of all cardiac procedures performed in North America, according to new data from the Society of Thoracic Surgeons Adult Cardiac Surgery Database (STS ACSD). A review of the data also shows that isolated mitral surgery in patients with the degenerative disease has greatly increased in the last few years and accounts for about two-thirds of all procedures.

“It gives us a really good snapshot of what’s going on with mitral valve surgery,” the study’s lead author, James S. Gammie, MD  told TCTMD. Operative mortality was observed to be low, at 2.0% for the entire cohort over the study period (2011-2016), with the highest operative mortality risks seen among patients with or without degenerative disease undergoing mitral valve replacement and the lowest in those undergoing repair.

Gammie and colleagues found that repair rates remained relatively stable over the study period among the overall cohort, but the repair rate for those with degenerative leaflet prolapse declined slightly from 83.5% in 2011 to 80.7% in 2016.

“Many of us think that’s an opportunity for improvement,” Gammie noted, adding, “Patients and/or their doctors are perhaps waiting a little bit too long to present and undergo surgery, because we found that almost half of patients had an EF of less than 60%, which makes that a Class I indication, [and] a third of them had A-fib.”

The study was published online July 18, 2018, in the Annals of Thoracic Surgery.

‘Plateau in Enthusiasm’ for Less-invasive Procedures

Gammie and colleagues analyzed data on 87,214 patients from more than 1,000 centers in North America who underwent an isolated mitral valve surgery.

During the study period, all mitral valve procedures increased by 24% in the overall group and by 44% among patients with degenerative leaflet prolapse. The compounded growth rate of all mitral surgeries was 4.4% per year beginning in 2011, which was more than double the growth rate of all cardiac procedures as a whole.

The vast majority of repair procedures involved annuloplasty rings. Among replacements, the use of bioprosthetic mitral valves increased over time, accounting for 70.8%. “We found that in the degenerative group, of all the replacements that were done about 16% had an unsuccessful attempt at repairing in the valve,” Gammie added. “It suggests that there are opportunities for improvement here in terms of improving success rates.”

The researchers also observed what Gammie described as “an apparent plateau in enthusiasm” for less-invasive, nonsternotomy mitral procedures, as evidenced by only a small increase in their use over the study period. The rate was 23% for these interventions during 2011-2016, which he told TCTMD is not much higher than the 20% rate that was noted in 2008 in the STS ACSD.

Looking at mitral valve procedures by volume, the data show that a small number of centers perform the majority of surgeries. Additionally, among hospitals performing isolated degenerative mitral procedures, only 147 of 1,125 (13%) performed 10 or more per year.

Source: TCTMD

#HeartCongress    #HeartConferences     #CardiologyConferences    #HeartSurgeryNews    LatestStats    #HeartHealth   #ForABetterHeartHealth    #LatestNews

Does 'good cholesterol' really protect heart health?

Traditionally, our high-density lipoprotein levels — also known as "good cholesterol" — have been considered a good indicator of heart health, particularly for women. Increasingly, however, research is casting doubts over this idea.

High-density lipoproteins (HDL) are molecules that transport fat through the body and to the liver so that it can be processed.

This helps to prevent excess accumulation, which is why it is also referred to as "good cholesterol."
High levels of HDL cholesterol have always been considered to be protective for heart health.

Women, in particular, tend to have higher levels of HDL cholesterol than men, but these do normally begin to decline when they reach menopause.

For this reason, specialists will often advise women on how to raise their "good cholesterol" levels at middle age. However, in recent years, some studies have suggested that HDL cholesterol may not, in fact, be as good for heart health as previous believed.

Now, researchers at the University of Pittsburgh Graduate School of Public Health in Pennsylvania — in collaboration with colleagues from other institutions — are questioning whether the ways in which we look at HDL cholesterol levels to predict cardiovascular risk may not be helpful for
women.

"The results of our study," says lead author Samar El Khoudary, "are particularly interesting to both the public and clinicians because total HDL cholesterol is still used to predict cardiovascular disease risk."

Questioning the usefulness of looking at "good cholesterol" as protective for the heart, the team's findings are published in the journal Arteriosclerosis, Thrombosis, and Vascular Biology of the American Heart Association.

Current notions may be inaccurate

The scientists analyzed the medical data of 1,138 women, aged 45–84, recruited through the Multi-Ethnic Study of Atherosclerosis.

"We have been seeing an unexpected relationship between HDL cholesterol and postmenopausal women in previous studies, but have never deeply explored it," notes El Khoudary.

At menopause, women's bodies go through several changes, especially hormonal fluctuations that can influence various physiological processes and measurements. El Khoudary and team believe that changes in estrogen levels, as well as other metabolic alterations, might lead to chronic inflammation, which can affect the quality of HDL particles over time.

The research assessed the number and size of HDL particles, as well as the total cholesterol that these particles carried, to establish whether high HDL levels were, in fact, protective for cardiovascular health in postmenopausal women.

El Khoudary and team also considered the influence of women's age at menopause and the time it took for women to transition to the postmenopausal period on HDL's contribution to heart health.

'Total HDL could mask significant risk'

Following their analysis, the researchers concluded that traditional methods of assesing HDL levels and their impact on cardiovascular health are not reliable enough in the case of postmenopausal women.

The scientists found a link between high HDL cholesterol and increased risk of atherosclerosis, particularly among women who had a greater age at the time of menopause and those at least 10 years into the postmenopausal period.

However, the researchers also found that a higher concentration of total HDL particles indicated a lower risk of developing atherosclerosis among the study participants.

But the results get even more complicated: having a high number of small-sized HDL particles, El
Koudary and team observed, seemed to have cardioprotective effects for all postmenopausal women, regardless of their age at menopause or how far into postmenopause they were.

Conversely, large-sized HDL particles indicated an increased risk of cardiovascular disease in the case of women who were close to menopause. This, the researchers explain, is likely due to the fact that at this time, the quality of HDL is affected.

But as women transition away from the menopause period, later in life, it may be that HDL quality increases once more, meaning that HDL cholesterol regains its protective effects.

"Identifying the proper method to measure active 'good' HDL is critical to understanding the true cardiovascular health of these women," notes senior study author Dr. Matthew Budoff.

El Khoudary explains, "This study confirms our previous work on a different group of women and suggests that clinicians need to take a closer look at the type of HDL in middle-aged and older women, because higher HDL cholesterol may not always be as protective in postmenopausal women as we once thought."

"High total HDL cholesterol in postmenopausal women could mask a significant heart disease risk that we still need to understand."

Samar El Khoudar

Soure: MedicalNewsToday

#HeartCongress2018    #HeartConferences    #CardiologyConferences   #CMEEvents #HeartHealth     #CardiovascularDisease    #GoodCholesterol    #BadCholesterol     #GoodIndicator    #ForABetterHealth

Large study reviews the cardiovascular benefits of walnuts

In recent years, studies have started pointing to nuts as a way to boost heart health, but most of them were observational with a limited sample size. Now, a systematic review of clinical trials spanning 25 years has confirmed that when it comes to cardiovascular health, nuts are the go-to food.



At Medical News Today, we've been unpacking the health benefits of nuts, one study at a time.
This delicious snack may be key for heart health and healthy aging, slashing the risk of stroke or coronary heart disease.

But the benefits of nuts do not stop here; some studies suggest that a handful of nuts may help us live longer, improve our memory, and strengthen our brain.

Now, scientists led by Marta Guasch-Ferré — a research associate in the Department of Nutrition at the Harvard TH Chan School of Public Health in Boston, MA — have carried out a large-scale review of numerous studies covering the link between nut consumption and heart health.

 

These "natural health capsules," as Guasch-Ferré called them in a study that MNT reported on last year, may do wonders for our cardiovascular system.

This is the main takeaway of the new review, which has been published in the American Journal of Clinical Nutrition.

Walnut-enriched diets protect the heart

This review updates the results of a previous meta-analysis that was published in 2009. It included 13 clinical trials.

Now, Guasch-Ferré and team have assessed the trials published since that point; this amounted to 26 randomized trials, summing up 1,059 participants with ages between 22 and 75.

Among the study participants, some were living with conditions such as high cholesterol, type 2 diabetes, metabolic syndrome, or obesity.

The scientists evaluated the benefits of a diet rich in walnuts and compared it with low-fat, Western, Mediterranean, and Japanese diets.

Walnut-enriched diets provided a more significant reduction in cholesterol levels and other markers of cardiovascular health when compared with these control diets.

More specifically, a diet rich in walnuts had a 3.25 percent greater reduction in total cholesterol levels, a 3.73 percent greater decrease in low-density lipoprotein (LDL) cholesterol, and a 5.52 percent greater reduction of triglycerides.

Also, levels of apolipoprotein B — which is the main protein found in LDL, or "bad," cholesterol — were lowered by 4.19 more percentage points than in control diets.

"Incorporating walnuts into the diet improved blood lipid profile without adversely affecting body weight or blood pressure," conclude the authors.

Strengths and limitations of the study

Walnuts' benefits may be down to their rich polyunsaturated, or "healthful," fat content, including essential omega-3 fatty acids, as well as to their wide variety of antioxidants.

Dr. Michael Roizen, the chief wellness officer in the Department of Preventive Medicine at the Cleveland Clinic in Ohio, weighs in on the findings.

"This updated review further strengthens the case that enjoying walnuts is a great (and tasty) way to add important nutrients to your diet while supporting the health of your heart."

Dr. Michael Roizen

But the review does have some caveats. The samples in most of the studies reviewed were fairly small, which may weaken the findings.

Also, some trials used a considerable amount of walnuts, which may be hard to stick to in a day-to-day setting, say the researchers.

Still, they highlight the fact that great benefits were noticed with even smaller amounts of walnuts — that is, fewer than 28 grams per day.

Finally, the research was funded by the California Walnut Commission, an agency of the State of California that works together with the Secretary of the California Department of Food and Agriculture to develop the nut market and support health research.

Source: MedicalNewsToday

#HeartCongress2018    #HeartConferences     #CardiologyConferences    #HeartHealth    #Walnuts    #CoronaryArteryDiseases     #HealthyDiet 

Healcerion 300L Wireless Portable Ultrasound Now Available in U.S.

Healcerion, the South Korean firm that introduced truly wireless ultrasound probes that work with smartphones and tablets, is releasing its SONON 300L ultrasound in the United States. The device was cleared last fall by the FDA and Healcerion has been working on manufacturing and preparing it for distribution.

The SONON 300L works with most Android and iOS phones and tablets, requiring the user to simply download the Healcerion app and to pair the ultrasound to the device being used. The ultrasound itself weighs 13 ounces (370 grams), is powered by a rechargeable battery that can scan continuously for up to three hours, and even features Wi-Fi and 3G/LTE capabilities.

 

The device can produce DICOM images, send the data to a hospital’s PACS (Picture Archiving and Communication System), and become a standard tool for a family physician, a doctor working outside of a clinical environment, and should be popular in urgent care clinics, remote areas, and home healthcare providers.

For more Details latest Technology and researches, Then you have to attend Heart Congress 2018 .
To Book you slots please Click Here

#Anesthesiology      #Cardiology      #Critical Care    #Medicine     #OB/GYN      #Surgery    #Latest_Innovations     #Medical_Devices     #HeartCongress2018    #HeartConferences   #CardiologyConferences   #HeartHealth

Next-generation of MitraClip approved for use in the USA

Abbott has received approval from the US FDA for a next-generation version of its MitraClip heart valve repair device used to reduce mitral regurgitation. A press release reports that the transcatheter clip-based therapy, now on a third-generation of product innovations, has been used to treat more than 65,000 patients worldwide over the last 10 years.

The next-generation MitraClip system is designed to provide cardiologists with advanced steering, navigation, and positioning capabilities for the clip, making it easier to use in difficult anatomies. The enhanced system is aims to allow for more precise placement during deployment, resulting in more predictable procedures, and additionally offers a second clip size with longer arms that expands the reach of the clip-based device. The additional clip size is designed to help doctors treat patients who have more complex anatomies when repairing the mitral valve.

Abbott received CE Mark for the next-generation device earlier this year, allowing for sale of the devices in the European Union and other countries that recognize this regulatory designation. Francesco Maisano (UniversitätsSpital Zürich, Switzerland), who was an early implanter of MitraClip, comments: “Physicians rely on MitraClip as an alternative to surgery for patients who aren’t surgical candidates and may need treatment to relieve their symptoms or to survive. The enhanced MitraClip design allows for even more precise navigation, accuracy, and stability during valve repairs, which may be important when treating people with more complex or advanced valve disease.”

Prior to the availability of MitraClip, people who were not eligible for the standard-of-care surgery to treat their mitral regurgitation could only manage their symptoms with medications that don’t stop the progression of the disease. Left untreated, the condition leads to a variety of life-altering symptoms and severe complications, and may ultimately lead to heart failure and death.

Michael Dale, vice president for Abbott’s structural heart business, comments: “Abbott engineers designed these enhancements based on feedback from doctors to improve device delivery and to treat more types of cases and anatomies. We are committed to helping people with mitral regurgitation return to living their best lives, and these advances will enable doctors to treat even more patients without surgery.”

Abbott recently began enrolment in the MitraClip EXPAND clinical study, a prospective study evaluating the safety and performance of the new MitraClip system in a contemporary real-world setting. Saibal Kar (Smidt Heart Institute, Cedars-Sinai, Los Angeles, USA) treated the first patient enrolled, and is the lead investigator of the study. EXPAND will enrol approximately 1,000 patients in more than 50 centres across the USA and Europe; interim results from the study are expected later this year.

For know the latest research work carried out in the field of Cardiology, Then you have to attend Heart Congress 2018. To book your slots, Please Register Here

#HeartCongress2018    #HeartConferences   #CardiologyConferences   #HeartHealth   #HeartSurgery   #MitralValve    #NewInnovations

Four ways innovation can help to beat heart disease

The statistics are staggering: non-communicable diseases (NCDs) account for 63% of deaths annually worldwide, and 80% of them occur in low- and middle-income countries, according to the World Health Organization.

 

NCDs are characterized by their long duration and slow progression, and impose substantial clinical and economic burdens on society. Saving lives and lifting financial strains requires an acceleration in the pace of drug discovery, then making those drugs affordable and accessible to patients everywhere. It takes approximately 10 years for a new medicine to make it to market, and each drug costs nearly $2.6 billion to develop. A sustainable approach to addressing cost and access must include fostering innovation to meet the evolving needs of patients globally. Some strategies to consider include:

• Laying out a consumer-centric, sustainable system that promotes value, affordability and innovation to create the most appropriate healthcare for all;

• Harnessing the collective impact of participant commitments by connecting like-minded stakeholders to pilot new disruptive models of care delivery and payment;

• Leveraging the collective data platforms and analytics of participant organizations to allow for evaluation of the models and their impact on patients across the health continuum; and

• Bringing together researchers, regulators and innovators to develop clinical trial designs that are more efficient and less costly, and capable of accelerating the introduction of medicines to market.



The traditional “one-drug, one-target” paradigm for drug discovery oversimplifies the underpinnings of disease. The capacity of high-performance computing to analyze multiple aspects of drug-target interactions is likely to be game-changing by reducing the time needed for drug development. Precision medicine could ultimately reduce the overall cost to the system by developing targeted and affordable medicines for patients.

As an evidence-based patient advocacy organization committed to health equity, the American Heart Association aims to ensure treatments are available, affordable and targeted.

To that end, the Association established the AHA Center for Accelerated Drug Discovery and partnered with Lawrence Livermore National Laboratory. Together, we are removing the guesswork from drug effectiveness by designing simulated environments for testing how drugs bind to their target proteins. Our aim is to reduce drug development time by up to 50%, as together we overcome the burden of drug discovery, cost and access.

Additionally, The AHA Institute for Precision Cardiovascular Medicine TM and Duke Clinical Research Institute’s data science team are working together to advance artificial intelligence and machine learning methods on its Precision Medicine Platform, powered by Amazon Web Services. Top scientists funded by DCRI grants are also developing state-of-the-art tools and data-harmonization methods to improve our ability to extract discoveries from data.

Attend Heart Congress 2018 to know more information regarding How to beat Heart Diseases.

#HeartCongress2018   #HeartConferences   #CardiologyConferences   #CME_Events   #BeatHeartDiseases   #ForABetterHeartHealth

Cardiac hybrid imaging is an effective tool for predicting myocardial infarction

According to a study published in Radiology, cardiac hybrid imaging with computed tomography (CT) and nuclear stress testing is an excellent long-term predictor of adverse cardiac events such as myocardial infarction in patients being evaluated for coronary artery disease.

Philipp A Kaufmann (University Hospital Zurich, Zurich, Switzerland) and colleagues looked at 428 patients who underwent hybrid imaging. During a median follow-up of 6.8 years, a total of 160 major adverse cardiac events—including 45 deaths—were observed in the final study population. Patients with matched findings (stenosis of 50% or more on CT angiogram with evidence of ischaemia on single photon emission tomography [SPECT] in the area of the heart to which the blocked vessel was supplying blood) had more than five times the risk of adverse events than those with normal findings. Patients with unmatched findings, or evidence of ischaemia but not in the area of the heart being fed by the stenotic artery, had three times the risk. Major adverse cardiac event rates were 21.8% for matched findings and 9% for unmatched—considerably higher than the 2.4% rate for normal findings.

The results show that cardiac hybrid imaging is an excellent long-term predictor of adverse cardiac events in patients evaluated for coronary artery disease. Kaufmann says that hybrid imaging findings could help guide treatment decisions, such as whether or not a patient should have a revascularisation procedure such as bypass or angioplasty. He comments: “In patients with multiple lesions or complex coronary anatomy, it is, in many cases, very difficult to correctly identify the culprit lesion. In a previous multicentre trial with hybrid imaging we were able to see that about one in five patients should be revascularised in another coronary artery than originally planned. The present study now documents the prognostic importance of the comprehensive assessment provided by hybrid imaging.”

The study supports CT angiography use for an initial, non-invasive evaluation of patients with known or suspected stable coronary artery disease. No additional imaging would be necessary if the results were normal. If a lesion was evident, then clinicians could employ a nuclear scan to assess ischaemia and take advantage of both modalities by fusing the results together to make a hybrid image.

“The strategy of direct referral to invasive coronary angiography without non-invasive imaging is obsolete. Even after documenting coronary artery disease with CT angiography, we need further non-invasive evaluation before deciding upon revascularization versus medication,” Kaufmann notes.

Kaufmann et al hope to run a trial to show that hybrid imaging can have a positive impact on patient outcomes. They are also looking at what they call “triple hybrid” imaging, which combines the CT angiography/SPECT hybrid with information on coronary artery shear stress. The shear stress information could help identify lesions that do not yet have an impact on ischaemia but will in the future.

For more information like this, then you have to attend Heart Congress 2018.  To Book your Slots, please Click Here

#HeartCongress2018   #HeartConferences   #CardiologyConferences   #Latest_Advancement     #Radiology

Did You Know About The Journey after Heart Transplantation

                          

Taking a healthy heart from a deceased donor and replacing it with a diseased heart of a patient is known as a heart transplant surgery. Patients who have end-stage heart failure usually go through heart transplant surgery.

A damaged or weak heart results in a heart failure. Heart Transplant is required when the heart is no more able to pump the required blood through the body and all the medication is no more effective.

Overview

Heart transplant is a life-saving measure for end-stage heart failure.

Patients go through a selection process to get the heart from donors since the supply is very less. To receive a new heart patient’s heart must be in end-stage and patient should be in a healthy condition to receive it.

Over the past decade the survival rates have increased to 88 percent for the first year after heart transplant and 75 percent survive for 5 years.

It is seen that most of the patients who have gone through Heart Transplant, have returned to their normal day to day activities.

Process : Heart Transplant

First the patient is referred to the Heart Transplant Center where the doctors confirm that the patient’s heart is at end stage.

When the center confirms that the patient is healthy enough to receive the heart or undergo a heart transplant surgery then the patient is added to the transplant waiting list.

When a suitable donor is found then the patient undergoes Heart Transplant surgery. It is after the surgery that the patient needs to be taken care for life long. Doctors suggest a lifelong medical care plan and frequent health check-ups.

Heart Transplant : Who Needs It

Mostly patients who are referred to heart transplant centres are the one have end-stage heart failure. Their heart failure might have been caused by:

• Hereditary conditions.
• Coronary heart disease.
• Viral infections of the heart.
• Damaged heart valves and muscles.

Heart Transplant : Risks Involved

Heart transplant is a lifesaving method which revives a patient with new hopes and life. But it comes with many side effects and life risks. Patients are supposed to undergo lifelong medical check-up plans proposed by the doctors. Many associated risks can be eliminated by having frequent health check-ups.

The risks of having a heart transplant include:

• Complications from medicines
• Infection
• Failure of the donor heart
• Cancer
• Problems that arise from not following a lifelong care plan after surgery

For more details, Please CLICK HERE

#HeartCongress2018   #HeartConferences   #CardiologyConferences  #HeartMeetings    #HeartTransplant   #HeartFailure    #Medicines    #HeartSurgery

Did You Know These Facts About Heart Bypass Surgery !!

What is coronary artery bypass surgery?

Coronary artery bypass surgery or Heart bypass surgery, is a process of replacing the blocked arteries that supplies blood to a human heart muscle. The operating surgeon on the patient uses blood vessels taken from another part of the human body to fix the blocked arteries. 213,700 coronary bypass surgeries were performed by the doctors in the United States in 2011.

When the coronary arteries gets blocked or damaged, then this surgery is performed. The oxygenated blood is supplied to the heart muscle through these coronary arteries. Heart failure risks are there if the blood flow to the heart is blocked and heart muscle is not able to work properly.

Heart Bypass Surgery: Different Types
Depending on how many of the arteries are blocked the doctor will recommend a certain type of bypass surgery

• Single bypass          :        Blockage of One Artery
• Double bypass        :        Blockage of Two Arteries
• Triple bypass          :        Blockage of Three Arteries
• Quadruple bypass :        Blockage of Four  Arteries

Heart Bypass Surgery: When is it required?

When the cholesterol level increases in our body, it starts depositing on the walls of the arteries which results in the flow of less blood to the human heart. The heart’s primary pump, the left ventricle is the most affected one in such cases.
If the coronary artery gets much narrowed and there is a risk of heart attack then your doctor can advise bypass surgery for that.

Heart Bypass Surgery: How is it determined?

Whether a person is ready for open-heart surgery or not is determined by a group of doctors and a cardiologist. Medical conditions like diabetes, emphysema, kidney disease and peripheral arterial disease (PAD) which can complicate surgery where doctors may not go for open-heart surgery.

Heart Bypass Surgery: Alternatives

Nowadays there are many alternatives to Heart Bypass Surgery. More methods are available today as below:

• Balloon angioplasty
• Enhanced external counterpulsation (EECP)
• Medications
• Diet and lifestyle changes

For information like this, come and join us @  World's Leading CME Accredited Event HEART CONGRESS 2018

#HeartCongress2018    #HeartConferences   #CardiologyConferences   #CMEConferences   #HeartHealth

Your Heart May Be Suffering From CHD !

                                    

Narrowing of the coronary arteries refers to as Coronary heart disease in which blood vessels that supply oxygen and blood to the heart gets narrowed. It is one of the major cause of deaths globally.
When cholesterol starts accumulating on the artery walls, it results in Coronary Heart Disease (CHD). In such cases, the arteries get narrowed, which results in the reduction of blood flow to the heart. Many times a clot gets formed which obstructs the flow of blood to the heart muscle.

                                         

CHD results in chest pain, myocardial infarction, shortness of breath, or heart attack. One of the most common types of heart disease in the United States is CHD, almost 3-4 lakhs death occurs every year due to CHD.

Some Facts and Figures :

• In 2008, 23.5 % of deaths were accounted for CHD in The US.
• About 7.35 Lakhs Americans have a heart attack each year as reported by the Centres for Disease Control and Prevention (CDC),.
• The initial symptoms or warnings include discomfort in breathing and chest pain.
• Angina and Heart attack are examples of coronary heart disease.

Coronary Heart Disease :

The human fist and the human heart muscle are of the same size.  A human heart pumps the blood to the lungs, where it collects oxygen. The oxygen-rich blood is then pumped back to the heart and which is then pumped to organs throughout the body through arteries.
The de-oxygenated blood is then sucked back into the heart via veins to send it to lungs to oxygenate it.

Heart’s network of blood vessels are the coronary arteries. The coronary arteries cover the surface of the heart, and Coronary arteries are the one which supplies the heart muscle with oxygen. Once this gets narrowed, the heart muscle gets low oxygen-rich blood.

Initially, this may not lead to any symptoms but after sometime when the fat keeps depositing and the arteries path keeps getting narrowed, symptoms like chest pain starts arising.

Symptoms :

1. Angina

The following are symptoms of angina:

• Chest pain
• Related symptoms
• Stable angina
• Unstable angina
• Variant angina

2. Shortness of breath (dyspnea)
3. Heart attack

Prevention

1. Dieting: Having fresh foods, vitamins rich foods and avoiding cholesterol-rich food helps a lot to avoid CHD.
2. Workout: Have some physical activity in your daily activity at least of one hour daily. It increases the blood circulation which in result burns the body fats.
3. People with CHD or diabetes should be in doctors regular touch and follow every instruction given by the doctor.

Sometimes Stay Hungry and Stay Healthy!

For latest updates on CHD, Come and join us @ Heart Congress 2018  this November @ Osaka.

#HeartCongresss2018    #HeartConferences   #CardiologyConferences   #HeartMeetings   #Osaka   #Japan   #HeartHealth    #CHD    #BetterHeartHealth

Look what Virtual Reality is to Offer for the Future of Cardiovascular Medicine

Virtual-reality (VR) tools are on the verge of becoming more commonplace in cardiovascular medicine, according to a state-of-the-art review. Once hindered by bulky technology, recent advances in computing mean that physicians are having a chance to explore new approaches to education, procedural planning and visualization, and patient care.

“Importantly, head-mounted displays have become untethered and are light enough to be worn for extended periods of time, see-through displays allow the user to remain in his or her environment while interacting with digital content, and processing power has allowed displays to keep up with human perception to prevent motion sickness,” lead author Jennifer N.A. Silva, MD (Washington University School of Medicine, St. Louis, MO)

Silva told TCTMD that while “the equipment itself has evolved so quickly,” even now “some of these headsets are clunky, and they’re big. They’re even heavy.” But much like car phones evolved into the array of mobile devices we carry with us today she also added, “what we’re already starting to see is that the hardware pieces are undergoing rapid improvement. It’s really exciting to push the boundaries [with the new devices], again keeping the patient in mind as the focus of everything we do” that makes for a more user-friendly experience.

VR, which is fully immersive, exists on the continuum of “extended reality” that’s currently being developed and applied. On the other end of the spectrum is so-called augmented reality, where virtual objects appear against a true background on a see-through display but can’t be altered. In between are merged and mixed reality, where it’s possible to interact with virtual objects on the backdrop of the real world, either through an immersive display or a see-through display, respectively.

All of these have their pros and cons, Silva said. “What’s exciting for me is to find the technology matching the need. And when you see those two things match and match well, there is a way to see patients’ anatomies and interact with those anatomies that we’ve just never been able to do before. The clinician in me has to believe that that improvement is going to end up in some way leading to some improvement for my patient. The scientist in me believes that that’s going to lead to [better understanding of heart] abnormalities in a deeper, fuller way.”

The Stanford Virtual Heart Project, among other things, is using an immersive VR headset to help pediatric patients and their families better understand cardiac anatomy as well as to teach medical students.

For preprocedural planning, the EchoPixel system (EchoPixel) enables a user wearing specialized glasses to visualize and manipulate cardiovascular anatomy. It employs True 3-D, a US Food and Drug Administration (FDA)-approved display, that works much like 3-D movie theaters and televisions.

Getting VR into procedures, though, is what excites Silva more. “That’s probably where it’s going to be most impactful to patients, and at the end of the day, that’s the Holy Grail,” she said. “That’s what we’re all chasing: how do we improve the way we take care of people?”

Silva herself has been working on Project ĒLVIS, a VR approach to imaging in electrophysiology. The system “not only empowers the interventional electrophysiologist to visualize patient-specific 3-D cardiac geometry with real-time catheter locations, but also allows direct control of the display without breaking sterility, which is a key advance,”

Another system, known as Realview (Realview Medical Imaging), has been used in the cardiac cath lab to generate real-time 3-D holograms using rotational angiography and transesophageal echocardiography.

To TCTMD, Silva said that over the next year she expects more and more of these technologies to become commercially available, gradually trickling into the “communal wisdom” of cardiovascular medicine.

Know time to share your views after reading this article, Let me know whether VR will play a crucial part in Cardiovascular medicine in the furture ? Shoot me your Thoughts.

For more information Like this and to discuses your ideas/views with the #Renowned_Cardiologists & #Researchers , Then you must attend Heart Congress 2018 which is scheduled on November 21-22, 2018 at Osaka, Japan.

Latest researches and advanced techniques are to be discussed at Osaka this year.

Book your slots and get a chance to be a part of this great gathering at Osaka this November -->Register Here

#HeartCongress2018   #LatestAdvancements   #UpcomingResearches  #InnovativeIdeas  #BettermentOfTheSociety   #ThisNovember   #Osaka_Japan

Hands-Only CPR Can Save Lives : A Quick Action of Life saving

About 70 percent of out-of-hospital cardiac arrests happen in homes. If you are called on to give CPR in an emergency, you will most likely be trying to save the life of someone you love. Learn how to save a life from below Steps:

Most people who experience cardiac arrest at home, work or in a public location die because they don't receive immediate CPR from someone on the scene. As a bystander, don't be afraid. Your actions can only help. When calling 911, you will be asked for your location. Be specific, especially if you’re calling from a mobile phone as that is not associated with a fixed address. Answering the dispatcher’s questions will not delay the arrival of help.

How to Give Hands-Only CPR (In-Two Steps)

If you see a teen or adult suddenly collapse, call 911 and push hard and fast in the center of the chest to the beat of any tune that is 100 to 120 beats per minute. Immediate CPR can double or even triple a person's chance of survival.

For life saving information like this and to participate in Hands-On Training sessions and Educate yourself, Then you have to be a part @ Heart Congress 2018 which is schedule on November 21-22, 2018 at Osaka, Japan.

Book your slots soon !!!!

#HeartCongress2018    #Workshops   #HeartHealth   #LifeSavingTechnique   #CPR   #EducatingOthers    #ThisNovember    #HeartConferences   #CardiologyConferences  #ShareyourIdeas

For Current Research and Advances in the Field of Cardiology : Heart Congress 2018

Diagrammatic representation of the Heart.

To Get to know the Latest Researched and Advancements in Cardiology Field, You Can Visit Heart Congress 2018.

Heart Congress 2018 is a International Conference With CME Accreditation which is to take place at Osaka, Japan on November 21-22, 2018.

For More Details and to Book your slots, Please CLICK HERE

#HeartCongress2018   #HeartConferences   #CardiologyConferences  #HeartEvents  #ForABetterHeartHealth   #LiveLong